Alba Angelina

Alba Angelina

Auto-generated profile, based on publicly available information

Alba Angelina

Department of Biochemistry and Molecular Biology, School of Chemistry Complutense University of Madrid Madrid Spain

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2022 in Clinical & Experimental Allergy
Verified
Journal Article
Open access
LMLeticia Martín‐Cruz
Leticia Martín‐Cruz
CSCarmen Sevilla‐Ortega
Carmen Sevilla‐Ortega
AAAlba Angelina
Alba Angelina
Jorge Dominguez‐AndresJorge Dominguez‐Andres
Jorge Dominguez‐Andres
MNMihai G. Netea
Mihai G. Netea
OPOscar Palomares
Oscar Palomares
Innate immune cells experience long lasting metabolic and epigenetic changes after an encounter with specific stimuli. This facilitates enhanced immune responses upon secondary exposition to both the same and unrelated pathogens, a process termed trained immunity. Trained immunity‐based vaccines (TIbV) are vaccines able to induce innate immune memory, thus conferring heterologous protection against a broad range of pathogens. While trained immunity has been well documented in the context of infections and multiple immune‐mediated diseases, the role of innate immune memory and its contribution to the initiation and maintenance of chronic allergic diseases remains poorly understood. Over the last years, different studies attempting to uncover the role of trained immunity in allergy have emerged. Exposition to environmental factors impacting allergy development such as allergens or viruses induces the reprogramming of innate immune cells to acquire a more pro‐inflammatory phenotype in the context of asthma or food allergy. Several studies have convincingly demonstrated that prevention of viral infections using TIbV contributes to reduce wheezing attacks in children, which represent a high‐risk factor for asthma development later in life. Innate immune cells trained with specific stimuli might also acquire anti‐inflammatory features and promote tolerance, which may have important implications for chronic inflammatory diseases such as allergies. Recent findings showed that allergoid‐mannan conjugates, which are next generation vaccines for allergen‐specific immunotherapy (AIT), are able to reprogram monocytes into tolerogenic dendritic cells by mechanisms depending on metabolic and epigenetic rewiring. A better understanding of the underlying mechanisms of trained immunity in allergy will pave the way for the design of novel trained immunity‐based allergen vaccines as potential alternative strategies for the prevention and treatment of allergic diseases.

3 August 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
CSCarmen Sevilla-Ortega
Carmen Sevilla-Ortega
AAAlba Angelina
Alba Angelina
LMLeticia Martín-Cruz
Leticia Martín-Cruz
MPMario Pérez-Diego
Mario Pérez-Diego
AMAngel Maldonado
Angel Maldonado
OPOscar Palomares
Oscar Palomares
Allergic sensitization and viral infections are risk factors for asthma development and progression. Sublingual vaccination with MV130, a whole heat-inactivated polybacterial preparation, protects against viral infections, but its impact on allergic sensitization and asthma development remains unknown. Here we show MV130 prevents house dust mite (HDM)-induced local type 2 immune responses and associated eosinophilic airway inflammation, conferring protection up to 9 weeks after vaccination. MV130 reduces pathophysiological and clinical asthma features in an in vivo experimental mouse model of HDM-induced allergic eosinophilic asthma, restoring normal airway functionality. MV130 impairs allergen-specific IgE sensitization and systemic type 2 inflammation endorsing type 1 and IL-10 responses. In human DCs, MV130 induces a transcriptomic and metabolic reprogramming, and restores non-pathological immune responses to allergens in healthy and asthmatic donors. Additionally, the adoptive transfer of MV130-stimulated BMDCs was sufficient to reproduce the protective features of the vaccine administration in vivo. Collectively, we show MV130 reduces allergic sensitization and eosinophilic asthma. Our findings support the exploration of mucosal interventions aimed at reducing the risk of allergen-induced asthma development.

28 October 2021 in Allergy
Verified
Journal Article
Closed access
PDF file
AAAlba Angelina
Alba Angelina
MPMario Pérez‐Diego
Mario Pérez‐Diego
AMAngel Maldonado
Angel Maldonado
BRBeate Rückert
Beate Rückert
MAMubeccel Akdis
Mubeccel Akdis
OPOscar Palomares
Oscar Palomares

7 March 2025 in Allergy
Verified
Journal Article
Open access
ARAndrés de la Rocha‐Muñoz
Andrés de la Rocha‐Muñoz
CBCristina Benito‐Villalvilla
Cristina Benito‐Villalvilla
DODavid Olivares
David Olivares
SSSofía Sirvent
Sofía Sirvent
MBMiguel Ángel García Brenes
Miguel Ángel García Brenes
OPOscar Palomares
Oscar Palomares
Background: A causal relationship between Crohn's disease (CD) and asthma is reported, but the underlying mechanisms are not fully understood. We sought to investigate the role of IgE and IgE‐mediated pathways in the pathophysiology of CD. Methods: 20 CD patients, 10 allergic patients without inflammatory bowel disease, and 10 healthy donors (HD) were included in the study. Total serum IgE was quantified by ELISA. Circulating IgE + and FcεRIα + immune cells, as well as specific CD4 + T cell populations, were determined by flow cytometry. Gene set enrichment signatures from available single‐cell (sc)RNAseq datasets of the intestine from CD patients were analyzed. Purified plasmacytoid dendritic cells (pDCs) from CD patients were cocultured with naïve CD4 + T cells to assess Tregs generation. Results: CD patients, similar to allergic non‐CD patients, displayed significantly higher numbers of circulating IgE + or FcεRIα + immune cells than HD. The percentage of blood IgE + or FcεRIα + pDCs was significantly higher in CD than HD and similar to allergic non‐CD patients. CD patients showed significantly higher numbers of effector memory CD4 + T cells and lower numbers of FOXP3 + Tregs than HD. scRNAseq data from CD patients confirmed that Tregs imbalance and overactivation of IgE‐mediated pathways take place also in gut tissues of children and adults, suggesting IgE could interfere in the pDC‐Tregs axis. In vitro functional experiments demonstrated that IgE‐crosslinking on pDCs from CD patients impairs Treg generation, which was restored by the anti‐IgE mAb omalizumab. Conclusions: IgE might play an unprecedented role in CD by impairing the capacity of pDCs to generate Tregs, which could represent a novel mechanism contributing to CD to be exploited for alternative therapeutic interventions.

21 December 2023 in Allergy
Verified
Journal Article
Closed access
CBCristina Benito‐Villalvilla
Cristina Benito‐Villalvilla
AAAlba Angelina
Alba Angelina
LMLeticia Martín‐Cruz
Leticia Martín‐Cruz